Skip to main content
. 2015 Dec 16;35(50):16479–16493. doi: 10.1523/JNEUROSCI.1585-15.2015

Figure 6.

Figure 6.

Effects of ErbB4 inhibition on GPSCs and EPSCs. A, B, Effects of ErbB4 inhibitors on GPSCs of newborn GCs. A1, A2, Mean amplitudes of feedforward GPSCs in control (black), Dox-treated (red), and AG-1478-treated (10 μm, green, denoted as “AG”) newborn GCs. Dox and AG-1478 were added in culture media from 4 dpi (A1) or 10 dpi (A2) and feedforward GPSCs were recorded at 7 dpi (A1) or 14 dpi (A2), respectively. B, Mean amplitudes of monosynaptic GPSCs at 14 dpi in newborn GCs grown under control conditions or under the condition in the presence of Dox, AG-1478, or anti-ErbB4 antibody (10 μg/ml, purple, denoted as “Ab-3”). Note that the three kinds of treatment reduced the GPSCs to a similar extent when the starting date of treatment was 4 dpi. C, D, Effects of AG-1478 on EPSCs in newborn GCs. Mean amplitudes (C1, D1) and PPR (C2, D2) of AMPA-EPSCs (C) and those of NMDA-EPSCs (D) in control, Dox-treated, or AG-1478-treated newborn GCs. Dox and AG-1478 were added in culture media from 7 dpi and EPSCs were recorded at 14 dpi. Tx., Treatment.